Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells

Bone Marrow Transplantation
E J YeohA J Gajjar

Abstract

We compared the efficacy, toxicity, and cost of topotecan-filgrastim and filgrastim alone for mobilizing peripheral blood stem cells (PBSCs) in 24 consecutive pediatric patients with newly diagnosed medulloblastoma. PBSCs were mobilized with an upfront window of topotecan-filgrastim for 11 high-risk patients (residual tumor > or =1.5 cm2 after resection; metastases limited to neuraxis) and with filgrastim alone for 13 average-risk patients. All patients subsequently underwent craniospinal irradiation and four courses of high-dose chemotherapy with stem cell rescue. Target yields of CD34+ cells (> or =8 x 10(6)/kg) were obtained with only one apheresis procedure for each of the 11 patients treated with topotecan-filgrastim, but with a mean of 2.3 apheresis procedures for only six (46%) of the 13 patients treated with filgrastim alone (P = 0.0059). The median peak and median total yield of CD34+ cells were six-fold higher for the topotecan-filgrastim group (328/microl and 21.5 x 10(6)/kg, respectively) than for the filgrastim group (54/microl and 3.7 x 10(6)/kg, respectively). Mean times to neutrophil and platelet engraftment were similar. Myelosuppression was the only grade 4 toxicity associated with topotecan-filgrastim mobiliz...Continue Reading

References

Mar 1, 1979·Computer Programs in Biomedicine·D Z D'Argenio, A Schumitzky
Jan 1, 1992·Journal of Hematotherapy·J G BenderL S Schwartzberg
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W BensingerC Weaver
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C F StewartC B Pratt
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T M WatersJ M Vose
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LegrosR Plagne
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerV Vlamis
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J von PawelR Gralla
May 21, 1999·Bone Marrow Transplantation·T C Shea
May 21, 1999·Bone Marrow Transplantation·E J Shpall
Dec 14, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L P AkardJ Jansen
Mar 9, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·K G Blume, E D Thomas
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S SienaC Carlo-Stella
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L Akard
Oct 12, 2000·Medical and Pediatric Oncology·C Rodriguez-GalindoP J Houghton

❮ Previous
Next ❯

Citations

Apr 9, 2002·Current Neurology and Neuroscience Reports·Michael D Weil
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clinton F StewartAmar Gajjar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.